Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VILMORIN-MIKADO USA, INC. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled within 1 distinct art unit by 1 distinct examiner. This reflects a very specific and focused prosecution effort within the biotechnology domain. The concentration in 1 distinct art unit indicates that the company's current patent activity is technically specialized.
The busiest examiner, KUMAR, VINOD, is responsible for the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the company's current interaction with the USPTO is centralized. This means the immediate success of the portfolio depends on the resolution of this 1 pending office action. Practitioners should note that the 1 distinct examiner will have a significant impact on the company's current patent strategy. The 1 pending office action represents the entirety of the company's current workload under review, making its outcome a critical milestone for the biotechnology-related portfolio. The 1 distinct art unit will provide the technical framework for the review of this application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUMAR, VINOD | 1 | 82.7% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18625917 | WILD ROCKET VARIETY SIMLOPS | KUMAR, VINOD | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18625917 | WILD ROCKET VARIETY SIMLOPS | KUMAR, VINOD | 26d |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18625917 | WILD ROCKET VARIETY SIMLOPS | KUMAR, VINOD | 1663 | §101 | Non-Final OA | 26d | Pending | Apr 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial